| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,250 | 5,550 | 09:47 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 35,000 | 6 | |||
| 22,200 | 30 | |||
| 20,000 | 83 | |||
| 16,000 | 532 | |||
| 15,000 | 15 | |||
| 5,550 | 918 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/88q.htm [/URL] | ||||
| 918 | 5,250 | |||
| 191 | 5,100 | |||
| 1.061 | 0,001 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 2.170 | 0,730 | 1.584 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 26.05.2026 | 17:35:52 | 5,250 | 34 |
| Tagesumsatz Xetra | - | 0 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | 4basebio Plc - Director Dealing | 301 | PR Newswire | 4basebio Plc - Director Dealing
PR Newswire
LONDON, United Kingdom, May 22
4basebio PLC("4basebio" or the "Company")
... ► Artikel lesen | |
| 20.05. | EARNINGS AND TRADING: 4basebio revenue surges in "step-change" year | 9 | Alliance News | ||
| 4BASEBIO Aktie jetzt für 0€ handeln | |||||
| 20.05. | 4basebio signs clinical supply deal for Phase II trial | 9 | Investing.com | ||
| 20.05. | 4basebio reports 81% revenue growth, narrows losses for 2025 | 8 | Investing.com | ||
| 20.05. | 4basebio steigert Umsatz um 81 % - Investitionen führen zu höherem Verlust | 13 | Investing.com Deutsch |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Di | Alaunos Therapeutics, Inc.: Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies | GlobeNewswire (Europe) | ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, including reductions in body weight and fat mass, improved insulin sensitivity, enhanced adipose function... ► Artikel lesen | |
| Di | Swedish Orphan Biovitrum AB: New analysis shows Tryngolza (olezarsen) reduced acute pancreatitis by 85% and triglycerides by 66% in severe hypertriglyceridemia | PR Newswire | STOCKHOLM, May 26, 2026 /PRNewswire/ -- Sobi (STO: SOBI) today announced results from a new analysis of the pivotal Phase 3 CORE and CORE2 trials, showing Tryngolza (olezarsen) reduced the... ► Artikel lesen | |
| 03:34 | Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC | GlobeNewswire (Europe) | SHANGHAI, May 26, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the... ► Artikel lesen | |
| Di | BioRestorative Therapies, Inc: BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data | GlobeNewswire (Europe) | Fully enrolled, randomized, double-blind, sham-controlled Phase 2 study has completed treatment administration in 99 patients; Company continues Phase 3 readiness activities following FDA Type B meeting... ► Artikel lesen | |
| Di | MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2026 | Business Wire |
MaaT013 (Xervyteg):
In May 2026, the Company was informed of a "negative trend" opinion on its Marketing Authorization Application from the Committee for Medicinal Products for Human Use... ► Artikel lesen |